MSA and Parkinson’s share alpha-synuclein pathology but progress very differently. Earlier detection could help researchers understand why – and reveal which proteins, cells and disease mechanisms offer the strongest therapeutic targets.
Multiple system atrophy (MSA) is a devastating condition that progresses rapidly, leaving patients and families to navigate an uncertain future. The rare neurodegenerative disorder is often fatal within five years and affects voluntary and involuntary functions, including movement, balance and even digestion or blood pressure regulation. A treatment that slows disease progression could mean more time for patients to remain independent, make plans and be with the people they love.
MSA, Parkinson’s disease and Lewy body dementia (LBD) share an association with misfolded alpha-synuclein protein. And yet, for example, MSA patients do not respond well to standard Parkinson’s therapies. For drug discovery researchers, the disease raises questions that reach beyond MSA: why does pathology involving the same protein behave so differently across neurodegenerative conditions? Which differences should determine what a drug targets?
Historically, MSA has been difficult to detect, with initial symptoms often hard to distinguish from Parkinson’s and tauopathies such as progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD). But advancements in early detection are creating new opportunities for researchers to study the disease in its earlier stages and strengthen patient selection for clinical trials. Understanding MSA’s distinct pathology and characteristics could help researchers identify stronger drug candidate targets and the cell types they need to reach.
What studying rapid progression could reveal
MSA’s rapid progression could allow researchers to track both biomarker and clinical changes over a relatively short 12- to 18-month period. Studying these changes together could help clarify how underlying pathology relates to worsening symptoms.
Several key questions can be addressed through research into MSA versus Parkinson’s. Why is MSA-associated alpha-synuclein pathology linked to faster disease progression? How do the different misfolded forms spread through the central nervous system (CNS)? Do they originate in the same brain regions or follow different routes as the disease develops?
Research into the speed and spread of pathology will help teams decide whether to focus on preventing further misfolding, interrupting the transfer of misfolded protein seeds, or targeting the cells in which pathology accumulates.
How differences in protein pathology could guide discovery
The distinct misfolded alpha-synuclein profiles associated with MSA and Parkinson’s suggest several possible therapeutic approaches.
Drug candidates could target different regions of alpha-synuclein that drive type 1 (Parkinson’s) or type 2 (MSA) misfolding. The goal would be to inhibit further misfolding driven by these seeds. Another approach is to investigate whether a drug could act against both profiles.
The affected cell types are also important. Parkinson’s-associated alpha-synuclein pathology is found predominantly in neurons, while MSA involves neurons as well as supporting glial cells. A strategy focused mainly on neurons may not fully address a patient’s MSA. Candidate selection should consider both the misfolded protein form and the cells a treatment would need to reach.
Parkinson’s-associated alpha-synuclein pathology is found predominantly in neurons, while MSA involves neurons as well as supporting glial cells.
For discovery teams, this provides a rationale for testing protein-directed and cell-directed approaches together, with the aim of achieving greater efficacy. Another priority is investigating whether blocking seed transfer across the CNS via cerebrospinal fluid (CSF) could limit the spread of disease.
Findings in MSA could inform drug discovery in Parkinson’s, LBD and other neurodegenerative disorders. The challenge, until recently, was diagnosing MSA early enough to study the disease’s progression. MSA diagnosis relied heavily on clinical symptoms with confirmation at autopsy. Seed amplification testing now enables researchers to identify alpha-synuclein pathology in living patients, creating opportunities to study the disease earlier and connect biological findings with clinical progression.
Why detection in living patients matters for research
MSA moves fast, and with so many fragmented approaches to diagnostic workups for neurodegenerative disease, patients can often lose precious time during their diagnostic journey.
Identifying an MSA-like alpha-synuclein profile in living patients provides additional biological information alongside clinical assessment. Amprion’s recent launch of SAAmplify-αSYN Plus, a CSF assay with improved detection of this MSA profile, is a notable advancement that can support and strengthen clinical research through better patient selection, earlier trial inclusion and biological stratification. For researchers developing a candidate against MSA-associated alpha-synuclein, it offers a more informed basis for identifying participants whose pathology aligns with the proposed target.
MSA moves fast, and with so many fragmented approaches to diagnostic workups for neurodegenerative disease, patients can often lose precious time during their diagnostic journey.
Moving further down the pipeline, the lack of actionable disease-modifying therapy biomarkers remains the biggest barrier to developing effective neurodegenerative treatments. These biomarkers can serve both as targets for therapeutic intervention and as early measures of therapeutic efficacy.
Building on advancements in detection, a key next step is to determine whether seed-related measurements could serve as exploratory biomarkers of treatment response. These measurements could help researchers assess how drug candidates affect misfolded alpha-synuclein seeds in the CNS.
Turning biological insights into development decisions
People living with MSA need treatments that can alter its rapid course. Early and accurate detection will drive research focused on disease biology, helping investigators ask better questions about MSA, Parkinson’s, Lewy body dementia and other related disorders.
The immediate priority is to turn those questions into testable therapeutic strategies to establish which misfolded forms to target, which cells a candidate must reach and whether interrupting seed transfer can affect disease progression. Better detection can inform those decisions and guide preclinical research.
More precise detection and a deeper understanding of MSA can help early-stage drug discovery researchers strengthen target selection and preclinical testing, with learnings extending far beyond MSA alone. For patients and families waiting for treatment, this work offers hope for new therapies that could slow the disease and lay the foundation for novel treatments in the future.
No comments yet